Internist - December 2015

 

Year

Rubinstein, et al, 2011 (16)

Rubinstein, et al, 2011 (16)

Kuijers, et al, 2010 (17)

Chung, et al, 2013 (18)

Chaparro, et al, 2013 (19)

Average Inclusion # of

Chaparro, et al, 2013 (19) (morphine, hydromorphone, oxycodo- ne, oxymorphone, and tapentadol)

Petzke, et al, 2014 (20) Buprenorphine, Oxycodone, Tapentadol (tramadol excluded)

Average Figure 1

Randomized controlled trials

Randomized controlled trials

Studies 4

3 Inclusion

Randomized controlled trials

Randomized controlled trials

Inclusion

Randomized controlled trials

Randomized controlled trials

Randomized controlled trials

# of Studies # of Patients Effect Size Standardized Mean Difference 6

6

1,402 1,323

-0.17

1 month -0.18

3 months

 Year

3 5

1,258 613

1,348

-0.19 -0.24 -0.18 -0.20

# of Studies # of Patients Effect Size Standardized Mean Difference 4

 Year

1,375 1,513 -0.26 -0.19 -0.22

# of Patients Effect Size Standardized Mean Difference

THE ORIGINAL INTERNIST 

(Continued on page 408) 

Page 1 | Page 2 | Page 3 | Page 4 | Page 5 | Page 6 | Page 7 | Page 8 | Page 9 | Page 10 | Page 11 | Page 12 | Page 13 | Page 14 | Page 15 | Page 16 | Page 17 | Page 18 | Page 19 | Page 20 | Page 21 | Page 22 | Page 23 | Page 24 | Page 25 | Page 26 | Page 27 | Page 28 | Page 29 | Page 30 | Page 31 | Page 32 | Page 33 | Page 34 | Page 35 | Page 36 | Page 37 | Page 38 | Page 39 | Page 40 | Page 41 | Page 42 | Page 43 | Page 44 | Page 45 | Page 46 | Page 47 | Page 48 | Page 49 | Page 50 | Page 51 | Page 52